Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Capecitabine,CapeStudy001,2022,USA,MDV,350,68,62,38,27.5,28,85,5,15,40,30,15,55,25,15,5,20,45,30,18,7,4,9,6,22,65,40,FAC,EC,Capecitabine + Docetaxel,Capecitabine,12,8,10,35,55,45,15,45,40,60,2
Capecitabine,Study002Cape,2023,Canada,Claim Database,420,72,58,42,28.1,31,82,7,12,38,32,18,52,28,14,6,18,42,33,20,8,5,10,7,25,68,42,AC,CMF,Capecitabine + Oxaliplatin,Capecitabine,10,9,11,38,58,48,12,48,40,65,3
Capecitabine,CapeStudy003,2022,UK,MDV,280,65,65,35,26.8,25,88,6,18,35,32,15,58,22,14,6,22,42,28,16,6,3,8,5,20,62,38,FEC,EC,Capecitabine + Cyclophosphamide,Capecitabine,14,7,9,32,52,42,18,42,40,55,2.5
Capecitabine,Study004Cape,2023,Australia,Claim Database,480,70,60,40,27.8,29,84,8,14,39,31,16,54,26,13,7,19,43,31,19,7,4,9,6,23,66,41,AC,FEC,Capecitabine + Docetaxel,Capecitabine,11,8,10,36,56,46,14,46,40,62,2.8
